Informal network of communication tools played an important role in sharing safety information on H1N1 influenza vaccine

Clinical Infectious Diseases

Volumn 51, Issue 7, 2010, Pages 873-874

  Nakada, Haruka ^a   Murashige, Naoko ^b   Matsumura, Tomoko ^a   Kodama, Yuko ^a   Kami, Masahiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Navitas Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; INFLUENZA VACCINE;

DRUG MONITORING; DRUG SAFETY; FISHER EXACT TEST; INFLUENZA A (H1N1); INFLUENZA VACCINATION; LETTER; PRIORITY JOURNAL; RISK;

AGED; DRUG TOXICITY; HUMANS; INFLUENZA VACCINES; INFORMATION DISSEMINATION; JAPAN; PHYSICIANS; VACCINES, INACTIVATED;

EID: 77957853321     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656297     Document Type: Letter

References (3)

1. Centers for Disease Control and Prevention. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1351-6.
2. Nakada H, Narimatsu H, Tsubokura M, et al. Risk of fatal adverse events after H1N1 influenza vaccination. Clin Infect Dis 2010; 50: 1548-9.
3. Narimatsu H, Hori A, Matsumura T, et al. Cooperative relationship between pharmaceutical companies, academia, and media explains sharp decrease in frequency of pulmonary complications after bortezomib in Japan. J Clin Oncol 2008; 26:5820-3.